CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Balance - beginning of period at Feb. 28, 2015	$ 988,558	$ 4,521,023	$ (5,406,675)	$ (45,850)	$ 57,056
BALANCE (in shares) at Feb. 28, 2015	988,558
Increase (Decrease) in Stockholders' Deficit
Net income			165,465		165,465
Other comprehensive income (loss):
Changes in Defined Benefit Plans, net of $4,842, $3,600 and $1,681 tax (expense) benefit at March 3,2018, March 4, 2017 and February 27,2016 respectively				(1,931)	(1,931)
Comprehensive income					163,534
Exchange of restricted shares for taxes	$ (2,045)	(15,461)			(17,506)
Exchange of restricted shares for taxes (in shares)	(2,045)
Issuance of restricted stock	$ 2,751	(2,751)
Issuance of restricted stock (in shares)	2,751
Cancellation of restricted stock	$ (420)	420
Cancellation of restricted stock (in shares)	(420)
Amortization of restricted stock balance		28,342			28,342
Stock-based compensation expense		11,164			11,164
Conversion of convertible debt instruments	$ 24,762	39,327			64,089
Conversion of convertible debt instruments (in shares)	24,762
Tax benefit from exercise of stock options and restricted stock vesting		22,466			22,466
Stock options exercised	$ 6,394	4,982			11,376
Stock options exercised (in shares)	6,394
Shares issued for EnvisionRx acquisition	$ 27,754	213,153			240,907
Shares issued for EnvisionRx acquisition (in shares)	27,754
Balance - end of period at Feb. 27, 2016	$ 1,047,754	4,822,665	(5,241,210)	(47,781)	581,428
BALANCE (in shares) at Feb. 27, 2016	1,047,754
Increase (Decrease) in Stockholders' Deficit
Net income			4,053		4,053
Other comprehensive income (loss):
Changes in Defined Benefit Plans, net of $4,842, $3,600 and $1,681 tax (expense) benefit at March 3,2018, March 4, 2017 and February 27,2016 respectively				5,464	5,464
Comprehensive income					9,517
Exchange of restricted shares for taxes	$ (809)	(5,446)			(6,255)
Exchange of restricted shares for taxes (in shares)	(809)
Issuance of restricted stock	$ 3,613	(3,613)
Issuance of restricted stock (in shares)	3,613
Cancellation of restricted stock	$ (424)	424
Cancellation of restricted stock (in shares)	(424)
Amortization of restricted stock balance		12,588			12,588
Stock-based compensation expense		9,989			9,989
Tax benefit from exercise of stock options and restricted stock vesting		(148)			(148)
Stock options exercised	$ 3,556	3,395			6,951
Stock options exercised (in shares)	3,556
Balance - end of period at Mar. 04, 2017	$ 1,053,690	4,839,854	(5,237,157)	(42,317)	614,070
BALANCE (in shares) at Mar. 04, 2017	1,053,690
Increase (Decrease) in Stockholders' Deficit
Net income			943,470		943,470
Other comprehensive income (loss):
Changes in Defined Benefit Plans, net of $4,842, $3,600 and $1,681 tax (expense) benefit at March 3,2018, March 4, 2017 and February 27,2016 respectively				7,255	7,255
Comprehensive income | Accounting Standards Update 2018-02					513
Comprehensive income					950,725
Cumulative Effect of Prospective Application of New Accounting Principle Net of Tax 1 | Accounting Standards Update 2016-09			11,729		11,729
Cumulative Effect of Prospective Application of New Accounting Principle Net of Tax 1 | Accounting Standards Update 2018-02			(513)	513
Exchange of restricted shares for taxes	$ (1,454)	(2,649)			(4,103)
Exchange of restricted shares for taxes (in shares)	(1,454)
Issuance of restricted stock	$ 13,856	(13,856)
Issuance of restricted stock (in shares)	13,856
Cancellation of restricted stock	$ (3,594)	3,594
Cancellation of restricted stock (in shares)	(3,594)
Amortization of restricted stock balance		18,365			18,365
Stock-based compensation expense		2,761			2,761
Amortization of performance-based incentive plans		1,667			1,667
Stock options exercised	$ 4,820	976			5,796
Stock options exercised (in shares)	4,820
Balance - end of period at Mar. 03, 2018	$ 1,067,318	$ 4,850,712	$ (4,282,471)	$ (34,549)	$ 1,601,010
BALANCE (in shares) at Mar. 03, 2018	1,067,318